Ewing's sarcoma: A combined approach in the management

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Ewing's sarcoma is a rare bone and soft tissue cancer primarily affecting children and young adults.
• Treatment strategies for localized Ewing's sarcoma involve a multimodal approach, typically including surgery, radiotherapy, and chemotherapy.

Purpose of the Study:

• To evaluate the efficacy of different treatment regimens for localized Ewing's sarcoma.
• To compare the outcomes of radiotherapy alone versus combination therapy (radiotherapy and chemotherapy).

Main Methods:

• Retrospective analysis of 27 histologically confirmed cases of localized Ewing's sarcoma.
• Patients were treated with either radiotherapy alone (13 cases) or a combination of radiotherapy and chemotherapy (14 cases).
• Chemotherapy regimens included single-agent cyclophosphamide or a combination of cyclophosphamide and actinomycin-D.

Main Results:

• Radiotherapy alone resulted in a 69.2% disease-free rate with a median of 10.4 months, and 53.8% developed metastases.
• Combination therapy showed improved disease-free survival (18.4 months) and a lower rate of metastases (42.9%).
• The combination of cyclophosphamide and actinomycin-D demonstrated no metastases in a 14-month follow-up, with only one case of residual disease.

Conclusions:

• Single-agent cyclophosphamide is inadequate for managing localized Ewing's sarcoma.
• The addition of actinomycin-D to cyclophosphamide significantly enhances disease-free survival.
• Further trials are needed to optimize radiotherapy doses and chemotherapy combinations for Ewing's sarcoma treatment.